Clinical trial registry record

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 5, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03386474
Last registry update
January 5, 2021
Status
Completed
Phase
Phase 3
Sponsor
Novartis Pharmaceuticals
Enrollment
151
Countries
United States, Puerto Rico
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
151
Population
ALL · 50 Years
Duration
2018-01-15 to 2018-09-06
Intervention
Brolucizumab 6 mg; Aflibercept 2 mg
Comparator
Not reported
Outcomes measured
Number of Participants With Ocular and Non-Ocular Treatment Emergent Adverse Events — Up to Week 24; Change of Loss in BCVA of 15 Letters or More From Extension Baseline at Each Post-baseline Visit — Extension Baseline,…; Change in BCVA From Extension Baseline at Each Post-baseline Visit — Extension baseline, Week 4, Week 8, Week 12, Week…; Patients With Positive q12w Treatment Status at Week 20 — Week 20; Change in Central Sub-Field Thickness (CSFT) From Extension Baseline at Each Post-baseline Visit — Extension Baseline,…; Percentage of Subjects With Positive Anti-drug Antibody (ADA) Status for Brolucuzumab 6 mg in Extension — Extension Bas…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON